Passive immunization against β-amyloid (Aβ) has become an increasingly desirable strategy
as a therapeutic treatment for Alzheimer's disease (AD). However, traditional passive …

Valproic acid (VPA) is a powerful teratogen causing birth defects in humans, including autism
spectrum disorder (ASD), if exposure occurs during the first trimester of embryogenesis. …

Endothelial cells of the blood–brain barrier form a structural and functional barrier maintaining
brain homeostasis via paracellular tight junctions and specific transporters such as P-…

The formation and accumulation of toxic amyloid-β peptides (Aβ) in the brain may drive the
pathogenesis of Alzheimer's disease. Accordingly, disease-modifying therapies for …

“Half of the secret of the cell lies outside the cell (Mina Bissell)”. This key aspect, over the
genetic influence on cancer, has been largely neglected in the context of oncology drug …

Background The brain of patients with advancing Alzheimer's disease is characterized by
two hallmarks, beta-amyloid plaques and neurofibrillary tangles (NFT) composed of hyper-…

Current methods for examining antibody trafficking are either non-quantitative such as
immunocytochemistry or require antibody labeling with tracers. We have developed a multiplexed …

Alzheimer’s disease (AD) is a devastating neurological degenerative disorder and is the
most common cause of dementia in the elderly. Clinically, AD manifests with memory and …

Cerebral amyloid angiopathy (CAA) is present in over half of the elderly population and in
80–90% of Alzheimer’s disease (AD) patients. CAA is defined by the deposition of beta …

Delivery of biologic drugs across the blood–brain barrier is becoming a reality. However, the
solutions often involve the assembly of complex multi-specific antibody molecules. Here we …